Posted February 19, 2019
Posted February 1, 2019
The clonoSEQ® Assay is now FDA-cleared and covered by Medicare for detecting and monitoring MRD in bone marrow samples from patients with multiple myeloma or B-cell ALL.
Posted January 22, 2019
View our Medicare coverage press release here. For more info about clonoSEQ, including test limitations, read the Technical Summary here. ABOUT ADAPTIVE BIOTECHNOLOGIES As a pioneer and leader in the field of immunosequencing, Adaptive Biotechnologies combines next generation sequencing (NGS) and proprietary bioinformatics to profile T-cell and B-cell receptors to drive groundbreaking research in cancer and other...
Posted January 15, 2019
The FDA has approved cabozantinib (Cabometyx) as a treatment for patients with hepatocellular carcinoma (HCC) who previously received sorafenib (Nexavar), according to the company developing the therapy, Exelixis. The approval was based on findings from the phase III CELESTIAL trial, in which overall survival (OS) was improved by 2.2 months with cabozantinib versus placebo. Median...
Bristol-Myers Squibb’s Sprycel® (dasatinib) Tablets Now Approved in Combination with Chemotherapy in Certain Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Posted January 11, 2019
Press Release See All Press Releases Sign up for Email Alerts Press Release RSS Sprycel is the first and only second-generation tyrosine kinase inhibitor for pediatric patients for the treatment of newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia in combination with chemotherapy Approval marks second pediatric leukemia indication for Sprycel 1 CATEGORY: CORPORATE/FINANCIAL NEWSWEDNESDAY, JANUARY 2, 2019 4:25 PM EST#FDA...